B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
about
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpointsPD-1 as an emerging therapeutic target in renal cell carcinoma: current evidenceTumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphomaCombining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challengesEffects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells.The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment.Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancerSOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expressionSurveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC.Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognosticImmune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.Induction of B7-H1 expression by human cytomegalovirus in extravillous cytotrophoblast cells and role of MAPK pathway.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment.NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway.Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
P2860
Q26801551-5006CBFB-D36F-44DE-A2BC-5B0824A3B760Q26865789-739B942D-4858-4374-9870-81C9D222604FQ30916013-EDF05CE7-A2CD-4D95-9711-98A0055D71DCQ34141476-3AA712CF-AF60-4ADE-8025-D0F8247ABA20Q34185078-F8A0F020-3066-494E-9847-A616EA14DA63Q34661815-9E74A98B-F357-4B1F-B325-7FFFCEC294C8Q35159355-45337563-2ABE-41E8-A32F-809F50866E21Q35664956-4A5D4BB1-6A9B-4548-AA50-5BDB86181AACQ35713265-21319D3F-A8AE-4115-A4AE-B4973C24EFE3Q36018118-AB591D78-CA6D-47C6-882F-CA3BB783C787Q36031954-5BE088E6-6E47-4ED5-A756-5DC42CDBDAD5Q36193035-CF3A9908-AC59-4F56-963A-C35D6975C8E9Q36522770-7A4A5A5E-D85E-4FA3-AD49-C7FD078153ECQ36642668-011184B1-BEAF-4F22-A5BC-F280249ABF54Q37086237-66DA563E-F9D5-4F96-9EE8-17AE6283533CQ37581437-1D8E27B5-0951-4216-B33A-0EA4DB51ACFCQ37675926-4827BBD2-4F61-4CC1-9853-B595E1311569Q37716378-76E740D1-54FF-49E7-9967-6E6F49698928Q38206386-82A4FBAE-30E6-4281-ABC5-E6CE46C4D43DQ38221107-E912BC03-2E72-4757-8F79-71A56EBEC97DQ38261285-83136EFB-4246-422B-8AA9-14D2235C0E14Q38607549-71A6EE5B-B134-4698-A3A4-03A717B584C5Q38634034-A58778AC-5681-406A-AB4A-5C4D17FE91ACQ38643567-8C1395C8-12E6-4BD0-A29C-82FF8C1082BFQ38646993-479D4EFD-4031-4A51-8C38-C0E0685D4639Q38668389-C80C131F-C08D-4B19-98FF-6D7A6DECF9A8Q38670099-A4C361E2-BCAA-4BCE-AD4D-8CED0411B167Q38743088-0E27BC6A-45A5-4A51-9942-D078ABAE4A26Q38956189-F7692C3A-2280-44E7-A970-68A5C2175654Q38996724-7BB72C67-9D9D-4BE3-AFA7-0B4F0D89B3EAQ39308923-2D8E80CD-9981-4583-8744-E25D03405245Q39868627-A2E06832-37FE-4FCE-8F0A-BC209D3B34AEQ40229039-2543F34A-BD18-4412-AECD-D70322571548Q41367801-173C3A9C-CB4C-4494-B0CC-531A7DA46332Q41998799-B5E8BCB9-E3E5-42A1-9104-227672A3E5FEQ42254184-D0400579-71F9-4B34-BFE2-2C9464E9F8EDQ44243898-46D7F2ED-C891-45E0-A639-2B444D16A29DQ46028514-4BA72CCD-AB53-4A54-8105-2E44271ACA80Q47120629-38B784BC-CA07-4971-8964-2B0FB455AA3EQ47424027-0B8A92E6-501E-442A-8996-A11E54375130
P2860
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
B7-H1 expression is regulated ...... lymphoma and Hodgkin lymphoma.
@en
B7-H1 expression is regulated ...... lymphoma and Hodgkin lymphoma.
@nl
type
label
B7-H1 expression is regulated ...... lymphoma and Hodgkin lymphoma.
@en
B7-H1 expression is regulated ...... lymphoma and Hodgkin lymphoma.
@nl
prefLabel
B7-H1 expression is regulated ...... lymphoma and Hodgkin lymphoma.
@en
B7-H1 expression is regulated ...... lymphoma and Hodgkin lymphoma.
@nl
P2093
P1433
P1476
B7-H1 expression is regulated ...... lymphoma and Hodgkin lymphoma
@en
P2093
Akifumi Takaori-Kondo
Masaharu Tashima
Momoko Nishikori
Ryo Yamamoto
Takashi Uchiyama
Tomomi Sakai
P2860
P304
P356
10.1111/J.1349-7006.2009.01302.X
P577
2009-08-01T00:00:00Z